Renal Dialysis Equipment Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMMD75 | Last Updated On: Jun 21 2022 | Available Formats

> Global Renal Dialysis Equipment Market Expected to reach a high CAGR during the forecast period 2022-2029: DataM Intelligence

Global Renal Dialysis Equipment Market is segmented by Equipment Type (Hemodialysis (HD) Equipment, Hemodialysis Machines, Dialyzers, Bloodline Systems And Catheters, Concentrates And Dialysis Solutions, Peritoneal Dialysis (PD) Equipment, Continuous Renal Replacement Therapy Systems, and Others), By End Users (Hospitals, In-Clinics & Dialysis Centres, Home Care Settings), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

 Market Overview

The Global "Renal Dialysis Equipment Market" size  is Estimedted to reach grow at high CAGR during the forecasting period (2022 -2029).    

Renal dialysis equipment is referred to the machines and apparatus used in the process that can temporarily replace the function of the kidney while patients await a transplant. Renal dialysis is an artificial method of maintaining the chemical balance of the blood when the kidneys have failed.  It gets rid of waste products, unwanted toxins, and excess fluid from the blood and balances electrolytes when kidneys fail to do their functions.   

 

Market Dynamics

The global renal dialysis equipment market growth is driven by the increasing prevalence of kidney diseases and the rate of end-stage cases globally is one of the major key drivers for the renal dialysis equipment market. Additionally, the favorable reimbursement and rise in technological advancement to enhance the treatments and medical services also influence the market.    

The rise in the number of end-stage renal disease patients (ESRD) will drive the market growth  

Globally, there has been an increase in the incidence of renal diseases, such as kidney diseases, in developed and developing countries. Dialysis is referred to patients with end-stage renal disorder (ESRD) or chronic kidney diseases. According to a 2018 study conducted by the University of California San Francisco, an estimated 2 million people worldwide suffered from end-stage renal disorders (ESRD).

According to a research study by Jennifer A Hirst et al., published in the British Journal of General Practice 2020, about 44.0% of people in the United Kingdom with chronic kidney disease (CKD) were undiagnosed without screening, and the prevalence of chronic kidney disease (CKD) stages 1-5 was 18.2% in patients aged above 60 years. Thus, the increasing burden of disease is expected to boost the market growth over the forecast period.

In the United States, the total Medicare spending on both chronic kidney disease and ESRD patients was more than $120 billion in 2017. For identified CKD (not ESRD), the total Medicare expenditure was $84 billion. Spending for ESRD patients totaled $35.9 billion, accounting for 7.2% of the overall Medicare-paid claims in the fee-for-service system, a share that has remained relatively constant for a decade.

The prevalence of recognized CKD cases, based on the analysis of Medicare data, has steadily risen year after year across all stages of the disease. From 2016 to 2017, the proportion of Medicare patients with recognized CKD increased from 13.8% to 14.5%.

The renal dialysis equipment market is expected to show good growth due to the expanding number of dialysis centers, growth in R&D expenditure for the development of new dialysis products, and increasing end-stage renal diseases. In January 2019, Baxter International Inc. received the US FDA approval for its clinical trial on-demand peritoneal dialysis solution generation system. The new system offers a good platform for patients to perform dialysis at home. Thus, the increasing burden of disease is expected to boost the market growth over the forecast period.

Complications and risks associated with dialysis is likely to hamper the market growth  

However, factors, such as complications and risks associated with dialysis and reimbursement issues, may hamper the market growth over the forecast period. Low blood pressure, or hypotension, during dialysis, occurs due to the temporary loss of fluids during treatment. If blood pressure drops during treatment, it may also notice dizziness, nausea, clammy skin, and blurry vision.  Muscle cramps can occur during dialysis due to a change in fluid or mineral balance. Low levels of sodium, magnesium, calcium, and potassium can all play a role in muscle cramping.

 

COVID-19 Impact Analysis

COVID‐19 is a very high transmission infectious disease with a variable prognosis in the general population. Patients in hemodialysis therapy are vulnerable to developing an infectious disease. For instance, according to a research article by Claudia Benedetti et al., published in Frontiers in Medicine Journal 2020, the study results indicate that patients with kidney disease could represent a risk factor in elderly patients for a more severe disease course. COVID-19 infects the kidneys and may induce acute kidney injury.

As per Johns Hopkins University, some people with COVID-19 showed signs of kidney damage, and even those who had no underlying kidney problems before were infected with the coronavirus. Moreover, about 30% of patients hospitalized with COVID-19 in New York and China developed moderate or severe kidney injury. In patients with COVID-19, signs of kidney problems include abnormal blood work and high levels of protein in the urine, which may lead to kidney damage in some cases and require dialysis.

As per the National Kidney Foundation Inc., in 2020, people who are on dialysis treatment may be at higher risk for severe disease from COVID-19. For severe cases, patient recovery may take six weeks or more. About 1% of infected patients will die from the disease.   Furthermore, in the United States, patients with pre-existing chronic kidney disease (CKD) were considered to be largely susceptible to COVID-19.

Segment Analysis

The hemodialysis (HD) equipment segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)       

Hemodialysis equipment adoption is steadily increasing due to the increasing prevalence of kidney failure patients. It is used to filter wastes and water from the blood. Thus, market players are found focusing on the developments of the new hemodialysis equipment that help in the growth of the overall market.     

In hemodialysis equipment, one needle will slowly remove the blood and transfer it to a machine called a dialyzer. The dialyzer is made up of a series of membranes that act as filters and a special liquid called dialysate. The membranes filter waste products from the blood, which are passed into the dialysate fluid. Most people need 3 sessions of hemodialysis a week, with each session lasting around 4 hours. This can be done in a hospital or at home. The dialyzer, or filter, has two parts, one for blood and one for a washing fluid called dialysate. A thin membrane separates these two parts. Blood cells, protein, and other important things remain in blood because they are too big to pass through the membrane. Smaller waste products in the blood, such as urea, creatinine, potassium, and extra fluid pass through the membrane and are washed away. 

In some cases of sudden or acute kidney failure, dialysis may only be needed for a short time until the kidneys get better. However, when chronic kidney disease progresses to kidney failure over time, kidneys do not get better and the patient will need dialysis for the rest of his life unless able to receive a kidney transplant. Chronic kidney disease was the underlying cause of death in around 3,600 deaths (21% of CKD deaths). Furthermore, technological advancements in healthcare are leading to the development of hemodialysis equipment with improved ergonomics.

 

Geographical Analysis

North America region holds the largest market share of the global renal dialysis equipment market

North America dominated the market due to the massive adoption of new technologies in the kidney dialysis division. There is also a boom in public healthcare expenditure and an increase in awareness programs about the availability of advanced treatments.

The incidence of kidney failure requiring dialysis or transplantation for end-stage renal disease (ESRD) in the U.S. ranks among the highest in the world. In 2017, there were 124,500 new cases of registered ESRD, compared to 125,408 the prior year. The rate of new cases of ESRD at 340.7 per million in 2017. This likely reflects the impact of improvements in the prevention or postponement of kidney failure in the U.S. The number of dialysis patients on the kidney transplant waiting list as of December 31, 2017, marked a third consecutive year of decline with an 8.8% reduction from the previous year. A total of 75,745 candidates are were on the list, with 85% of whom were awaiting their first kidney transplant. This decrease almost certainly resulted from the Kidney Allocation System (KAS) policy changes that took effect on December 4, 2014.

Some of the market players involved in the US market include DaVita, Baxter International, Medtronic, and U.S. Renal Care. These players adopted various strategies, such as collaborations, mergers, acquisitions, and product innovations, to maintain their market position. For instance, in March 2017, the US renal care announced the expansion of its dialysis clinic in Dallas. This expansion allowed the company to broaden its business operations and increase its customer base. Thus these factors are driving the growth of the market in the forecast period.

 

Competitive Landscape

The renal dialysis equipment market is the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Fresenius Kabi AG, B. Braun Melsungen AG, Baxter International Inc., Nikkiso Co. Ltd, Nipro Corporation, Asahi Kasei Corporation, Medtronic PLC, and Rockwell Medical, Teleflex Incorporated, Medivators Inc among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the renal dialysis equipment market globally. For instance, in December 2020, Medtronic PLC launched the first and only pediatric and neonatal acute dialysis machine in the United States.

Fresenius Kabi AG.

Overview:

Fresenius Kabi Aktiengesellschaft produces infusion therapy and clinical nutrition products. The Company offers generic drugs, anesthetics, analgesics, anti-invectives, and medical devices for blood collection and processing. Fresenius Kabi operates in Germany.   

Product Portfolio:

2008T BlueStar Hemodialysis Machine:  The 2008T BlueStar hemodialysis machine is designed to potentially provide simpler operation and maintenance with greater user control. Auto Prime simplifies the priming process with fewer steps and user touches than current priming methods. Auto Start allows users to set a specific time each day when the 2008T BlueStar machine will automatically power up.

 

Trending Topics

Brazil Renal Dialysis Equipment Market

Haemodialysis Equipment Market

Urinary Catheters Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest